Deciphera Pharmaceuticals, Inc. (DCPH) News
Filter DCPH News Items
DCPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DCPH News Highlights
- For DCPH, its 30 day story count is now at 4.
- Over the past 14 days, the trend for DCPH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest DCPH News From Around the Web
Below are the latest news stories about DECIPHERA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate DCPH as an investment opportunity.
Deciphera Pharmaceuticals Inc (DCPH): A Deep Dive into Its Performance PotentialUnraveling the Factors That Could Limit Future Growth |
Deciphera Pharmaceuticals (DCPH): An Intriguing Value Play with a Modestly Undervalued Market ...Scrutinizing the Intrinsic Value of Deciphera Pharmaceuticals |
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., September 15, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that in connection with the hiring of Dashyant Dhanak, Ph.D., Executive Vice President and Chief Scientific Officer, the Compensation Committee of Deciphera’s Board of Directors approved the grant of a stock option to purchase 65,900 shares of Deci |
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders have endured a 66% loss from investing in the stock three years agoThe truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three... |
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right NowBiotech stocks may offer some of the most explosive opportunities on the market. |
3 Under-the-Radar Biotech Stocks to Buy in 2023Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer. Deciphera Pharmaceuticals (NASDAQ: DCPH), Mirati Therapeutics (NASDAQ: MRTX) and MacroGenics (NASDAQ: MGNX) are lesser-known biotech companies with significant potential since they focus on oncology therapies. |
Why Shares of Deciphera Pharmaceuticals Rose This WeekShares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. ET, according to data provided by S&P Global Market Intelligence. All but $1 million of the revenue came from sales of gastrointestinal stromal tumor (GIST) therapy Qinlock. Qinlock is approved as a fourth-line treatment for GIST, a type of stomach cancer. |
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives RevenuesDeciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales. |
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue EstimatesDeciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 8.06% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |